CompletedNot Applicable

23andMe IPF Research Study

United States690 participantsStarted 2020-06-05

Plain-language summary

The long term goal of this study is to increase genetic understanding of IPF to enable the development of an effective drug for IPF that can improve the lives of those living with the condition.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have been diagnosed with IPF or Hermansky-Pudlak syndrome (HPS) * Are 18+ years old * Live in the US Exclusion Criteria: \- Have been diagnosed with sarcoidosis or hypersensitivity pneumonitis

What they're measuring

IPF Symptom Progression Baseline

Timeframe: Baseline

IPF Symptom Progression 3 month follow-up

Timeframe: 3 months post baseline

IPF Symptom Progression 6 month follow-up

Timeframe: 6 months post baseline

IPF Symptom Progression 9 month follow-up

Timeframe: 9 months post baseline

Trial details

NCT IDNCT05028894

Sponsor23andMe, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-05-05

View on ClinicalTrials.gov More Idiopathic Pulmonary Fibrosis trials